Parimmune
Who are we?
The corner stone of Par’Immune is the development of P28GST as immunotherapeutic platform for autoimmune and inflammatory diseases such as Crohn’s disease, ulcerative colitis, and psoriasis. The company aims to perform two Phase 2b clinical trials in order to reach the clinical proof of concept. A Phase 2b trial in IBD will be initiated during the second half of 2018 and a Phase 2b trial in Psoriasis will be filed by the end of 2018.